Document Detail

Dorzolamide hydrochloride and visual function in normal eyes.
MedLine Citation:
PMID:  9535619     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To determine by a pilot study whether standard treatment with the topical carbonic anhydrase inhibitor dorzolamide hydrochloride influences visual function under normal breathing conditions, during carbon dioxide inhalation, or during hyperventilation, and to establish criteria for future larger-scale studies. METHODS: We enrolled 12 normal subjects into this randomized double-masked placebo-controlled crossover study. Each subject was treated with either dorzolamide 2% or placebo, three times daily, for 4 days. After a 2-week washout period, the alternative topical agent was used under identical testing conditions. On day 2 of each treatment phase, contrast sensitivities to sinusoidal gratings of 1 and 4 cycles per degree (cpd) were assessed. On day 4, mean deviation values from full-threshold 10-2 visual fields were obtained. Three sets of each visual function test were obtained before each treatment phase, and in sequence on each testing day, during normal breathing (baseline), inhalation of carbon dioxide-enriched air, and hyperventilation while intraocular pressure was monitored. RESULTS: Contrast sensitivity at 4 cpd decreased significantly (P < .01) during carbon dioxide supplementation with placebo but showed no significant change with dorzolamide. The decrease in contrast sensitivity accompanying hyperventilation was attenuated (by nearly 50% at 1 cpd) during dorzolamide treatment. Dorzolamide treatment was associated with higher perimetry mean deviation values under each treatment condition and was statistically significant (P < .05) at baseline. CONCLUSIONS: Dorzolamide appears to enhance contrast sensitivity in normal subjects during physiologic hypercapnia and hypocapnia at 4 and 1 cpd, respectively. Also, under normal breathing conditions, dorzolamide therapy increases perimetric light sensitivity.
W E Sponsel; J Harrison; W R Elliott; Y Trigo; J Kavanagh; A Harris
Related Documents :
1810619 - Physiological effects of wearing mouthguards.
9051169 - Emission of extremely strong magnetic fields from the head and whole body during orient...
22831159 - Therapeutic exercise in cancer cachexia.
4006549 - Periodic breathing triggered by hypoxia in normal awake adults. modification by naloxone.
22975529 - Vitamin d in exercise: physiologic and analytical concerns.
12748569 - Rate of nitrous oxide exchange across the middle ear mucosa in monkeys before and after...
3370399 - Treadmill protocols for determination of maximum oxygen uptake in runners.
18382039 - Inflated perceptions of physical activity after stroke: pairing self-report with physio...
18337359 - Prevention of overuse injuries by a concurrent exercise program in subjects exposed to ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  American journal of ophthalmology     Volume:  123     ISSN:  0002-9394     ISO Abbreviation:  Am. J. Ophthalmol.     Publication Date:  1997 Jun 
Date Detail:
Created Date:  1998-04-07     Completed Date:  1998-04-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370500     Medline TA:  Am J Ophthalmol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  759-66     Citation Subset:  AIM; IM    
Department of Ophthalmology, University of Texas Health Science Center, San Antonio, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carbonic Anhydrase Inhibitors / administration & dosage*
Contrast Sensitivity / drug effects,  physiology*
Cross-Over Studies
Double-Blind Method
Hypercapnia / physiopathology
Hypocapnia / physiopathology
Intraocular Pressure / drug effects
Ophthalmic Solutions
Pilot Projects
Sulfonamides / administration & dosage*
Thiophenes / administration & dosage*
Visual Fields / drug effects,  physiology*
Reg. No./Substance:
0/Carbonic Anhydrase Inhibitors; 0/Ophthalmic Solutions; 0/Sulfonamides; 0/Thiophenes; 130693-82-2/dorzolamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of chronic nitrate treatment on retinal vessel caliber in open-angle glaucoma.
Next Document:  Distribution of central corneal thickness and its association with intraocular pressure: The Rotterd...